🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The effect of tumor downsizing on surgical complexity during nephrectomy after immune checkpoint inhibitors for metastatic renal cell carcinoma link.springer.com/article/10.100… This multicenter retrospective study aimed to assess the oncological outcomes of delayed nephrectomy after

Our first Florence Multidisciplinary Expert Meeting on RCC Long story short: 2 days full of #science & #emotions, surrounded by experts and brilliant researchers in the field, all part of a wonderful #family aiming to share knowledge and expertise to advance #RCC care. Embraced by the beauty of Florence.

💡Updated European Association of Urology (EAU) Guidelines on the Use of #Adjuvant Immune Checkpoint Inhibitors and #Subsequent Therapy for Renal Cell Carcinoma 👉europeanurology.com/article/S0302-… European Urology #JensBedke Yasmin Abu-Ghanem Laurence Albiges Umberto Capitanio Saeed Dabestani Milan Hora Tobias Klatte #TeeleKuusk

Safety and efficacy of neoadjuvant durvalumab plus gemcitabine/cisplatin or carboplatin in patients with operable high-risk upper tract urothelial carcinoma: the iNDUCT trial out on JCO ascopubs.org/doi/abs/10.120… Phase II trial evaluated the safety and efficacy of neoadjuvant

Merci aux intervenants Morgan Roupret Pignot Géraldine Evanguelos Xylinas Roubaud Guilhem Wes Kassouf Alejandro (Ale) Berlin Genevieve LOOS Paul Sargos ➡️ Vidéo dédiée aux patients Cancer Vessie France Bladder Cancer Advocacy Network BladderCancerCanada Bladder Cancer Canada | Montreal Walk World Bladder Cancer Patient Coalition Fight Bladder Cancer

Safety and Efficacy of Neoadjuvant Durvalumab Plus Gemcitabine/Cisplatin or Carboplatin in Patients With Operable High-Risk Upper Tract Urothelial Carcinoma: The iNDUCT-GETUG V08 Trial ascopubs.org/doi/10.1200/JC… This phase II trial evaluated the safety and efficacy of neoadjuvant

Elegant discussion by Pignot Géraldine putting into perspective importance of risk/safety assessment & NIAGARA trial showed no additional toxicity with durvalumab. Gem Cis Durva is the new SOC. Raises question of possibly overstatement with adjuvant IO in NIAGARA trial for patients

Pathological CRs from the neoadjuvant MIBC trials NIAGARA discussant presentation from Pignot Géraldine UroToday.com #EAU25

#EAU25: #Discussant: #NIAGARA - Surgical outcomes and neoadjuvant safety with perioperative durvalumab for #MIBC. Presentation by Pignot Géraldine Institut Paoli-Calmettes (IPC). Written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/4bLcWDx European Association of Urology (EAU)

Full house appreciation post starring Pignot Géraldine. Just 🤩

📺EAU25: EAUTV on AURORAX 0087A study UROONCO RCC chief editor Dr. Carmen Mir talks to Assoc. Prof. Saeed Dabestani on the AURORAX 0087A study. ▶️ Watch the conversation here: eaucongress.uroweb.org/eau25-eautv-on…

👩‍🦰👩‍⚕Donner des ELLES à la santé : une réalité portée par le Syndicat UNIPA ! Aujourd’hui, notre secrétaire générale Lise Mantisi a brillamment représenté le syndicat des Infirmiers en Pratique Avancée (UNIPA) lors de la table ronde “Égalité professionnelle à l’hôpital :

Donner des Elles à la santé… 3 établissements s’engagent pour l’égalité entre les femmes et les hommes et contre les violences sexistes et sexuelles Hospitalité Saint-Thomas de Villeneuve Centre Hospitalier Montperrin Hôpital Aix-Pertuis 🙏 ARS Paca Aix-en-Provence

The authors of a new Perspective argue that severing the long-standing ties and scientific collaborations between the United States and the World Health Organization (WHO) and slashing U.S. financial support will have catastrophic effects on both domestic and global health. Read the full Perspective:

Le programme de FOCUS 2025 meets Spain est disponible : focus-meeting.fr/programme/ Présidents @ecastromarcos et Karim Bensalah Nous vous attendons nombreux pour cette nouvelle édition ! 🗓 9 et 10 octobre 2025 📍Centre de congrès Pierre Baudis, Toulouse

Let's kick off #RENALC25 with a first case challenge! Manuel has a small renal mass in his only functional kidney. What now? 👉 Check out the case, vote on your preferred treatment option: renalc.mirrorsmed.org/en/single-case… and see what Dr. Pignot Géraldine would do!📽️ Want to be part of more case

Dr. Yannick Neuder SantExpo Ministère de la Santé et de l'Accès aux soins Ministère Enseignement supérieur et Recherche Catherine Vautrin Frédéric Valletoux Agnès Firmin Le Bodo Nicole Dubré-Chirat Ilona Denis FHP Remy mazzocchi #SantExpo2025 | Table Ronde avec #DonnerDesEllesÀLaSanté sur "Égalité professionnelle à l'hôpital : quelle réalité en 2025 ?" 👩‍⚕️ Ilona Denis « 15,81 % des ESI qui estiment avoir été victimes de VSS pendant leur formation » ❌

How exciting to see all these new data at #ASCO25! 👀 Interested to hear how these data are translated to your clinical practice? 👂 At the Global Forum on GU Oncology, the impact of the latest findings on #RenalCancer, #BladderCancer and #ProstateCancer are discussed in a

Friday : #SP case obs at UIC Urology with Markus Grabbert 🇩🇪, Saturday : boat trip with Alberto Briganti 🇮🇹 & Maria J. Ribal 🇪🇸, Monday with Andrea Tubaro 🇮🇹 & Pignot Géraldine 🇫🇷, Tuesday : on my way to #CILR25 #international learning and teaching is at the base of our community.

Amazing presentation of Ploussard Guillaume at JUM / Marseille Key messages : 📛 No de-escalation for high risk patients if negative PET-PSMA (NPV 80% in this population with a high prevalence, suggesting that we can miss 20% of pN+ without eLNPD) ❓️What about intermediate risk ?